Get the Finder app 🥳

Track your credit score

Free

Install
finder.com.au

How to buy Gilead Sciences shares | US$60.03

Own Gilead Sciences stock in just a few minutes.

Updated

Fact checked
Buy Gilead shares Learn more

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Gilead (GILD) is a leading biotechnology business headquartered in the US and listed on the NASDAQ. Its share price jumped during the coronavirus pandemic after it receieved the green light from the US Food and Drug Administration (FDA) for funding towards its experimental COVID-19 cure Remdesivir.

Although test trials remain underway, researchers at Chicago University announced in mid April that test patients of the drug had seen rapid recoveries of respiratory and fever symptoms, with most patients discharged in a matter of days.

How to buy shares in Gilead Sciences

  1. Compare share trading platforms. To buy shares in a US company from Australia you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences. Find the share by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$60.03, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

Price details for Gilead Sciences (GILD)

Open $59.64 Previous close $59.5
High $60.05 Change $0.53
Low $59.2789 Change % 0.891%
Close $60.03 Timestamp 1606500000
Volume N/A GMT offset 0

Gilead Sciences stock price

Use our graph to track the performance of GILD stocks over time.

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

  • $0 brokerage for US stocks
  • Trades starting from $50
  • Fractional shares
  • Copy top traders
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
Finder Award
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
Go to site
More Info
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Go to site
More Info
CMC Markets Stockbroking
Finder Award
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
Go to site
More Info
loading

Compare up to 4 providers

Should I buy Gilead Sciences shares?

Technical Analysis of Gilead Sciences by TradingView

This is not a recommendation, it represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Gilead Sciences company summary

Information last updated 2020-11-25.

Gilead Sciences (GILD) is a leading Biotechnology business based in the USA. Gilead Sciences (GILD) is listed on the NASDAQ and employs 11800 staff.

Profile

Industry Drug Manufacturers—General Currency symbol $
Code GILD Country name USA
Type Common Stock Country ISO US
Name Gilead Sciences, Inc ISIN US3755581036
Exchange NASDAQ CUSIP 375558103
Currency code USD Sector Healthcare
Currency name US Dollar Full-time employees 11800

Detailed company information

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site